PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-40

  1. 4,343 Posts.
    lightbulb Created with Sketch. 6885
    Torpy - great post. It makes sense when you reflect on it and get passed the 'delay'.
    There is rationale behind it and dovetailing the data to the main trials and what the FDA and EMA will find compelling.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.